1-[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin-4-yl]-2-methyl-1H-benzoimidazole-5-carboxylic acid | 1067717-02-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin-4-yl]-2-methyl-1H-benzoimidazole-5-carboxylic acid
• 英文别名: 1-[1-[(4-Chloro-3,5-diethoxyphenyl)methyl]piperidin-4-yl]-2-methylbenzimidazole-5-carboxylic acid
• CAS: 1067717-02-5
• 化学式: C₂₅H₃₀ClN₃O₄
• 分子量: 471.984
• InChiKey: SCAJVNFQEAFTIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  76.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES
  申请人：Bleicher Konrad

  公开号：US20080249101A1

  公开（公告）日：2008-10-09

  This invention relates to compounds of the formula wherein A, R 1 to R 3 are as defined in the specification and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridine and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A，R1至R3如规范中所定义，G为苯并咪唑，喹喔啉，苯并三唑，二氢咪唑[4,5-c]吡啶和二氢异吲哚酮基团，如规范中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病。
• 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2142528A1

  公开（公告）日：2010-01-13
• US7799806B2
  申请人：——

  公开号：US7799806B2

  公开（公告）日：2010-09-21
• [EN] 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS<br/>[FR] DÉRIVÉS D'ACIDE 1-(1-BENZYLPIPÉRIDIN-4-YL)BENZIMIDAZOLE -5-CARBOXYLIQUE POUR LE TRAITEMENT DU DIABÈTE SUCRÉ
  申请人：HOFFMANN LA ROCHE

  公开号：WO2008122510A1

  公开（公告）日：2008-10-16

  [EN] This invention relates to compounds of the formula (I) wherein A, R¹ to R³ are as defined in the specification and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridinone and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
  [FR] La présente invention concerne des composés de formule (I), dans laquelle: A, R¹ à R³ sont tels que définis dans la description et G est un groupe benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridinone et dihydro-isoindolone tel que défini dans la description, ainsi des leurs sels pharmaceutiquement acceptables. L'invention concerne également des compositions pharmaceutiques contenant de tels composés, leur procédé de préparation et leur utilisation pour le traitement et/ou la prévention de maladies associées à la modulation des récepteurs SST de sous-type 5.